natgillin/translations-raw huggingface dataset:
Another embodiment includes method and apparatus for neuromodulatory regulation of effector organs by modulation of spinal neurons, having anode and cathode sources, having a spinal circuit for biasing a spinal electrode at a first polarity and biasing a distal reference electrode at a second polarity, and having a neural circuit for biasing a nerve associated with the muscle, the neural circuit having a charge-balancing electrode device having a first and second neural electrodes for limiting the polarizing effect of current flow in the nerve, the neural circuit biasing the first neural electrode to the second polarity and the second neural electrode at the first polarity, wherein the spinal electrode and the second neural electrode are connected to one of the sources and the first electrode is connected to the other of the sources, for activation of the effector organ of interest, as described in embodiments above. 
Sustav za modulaciju spinalnih neurona povezan s regulacijom djelovanja efektorskih organa u tijelu kralješnjaka, sustav obuhvaća: prvu stimulacijsku komponentu konfiguriranu na način da omogućava stimulaciju živca povezanog s ciljnim efektorskim organom; pri čemu je prva stimulacijska komponenta konfigurirana na način da pruža električnu stimulaciju istosmjernom strujom; te drugu stimulacijsku komponentu konfiguriranu na način da omogućava stimulaciju istosmjernom strujom povezanu s modulacijom navedenog ciljanog efektorskog organa; pri čemu je druga stimulacijska komponenta konfigurirana na način da pruža spinalnu kontinuiranu stimulaciju konstantnom istosmjernom strujom; i kontrolnu komponentu konfiguriranu na način da simultano kontrolira doseg struje koju dovode prva i druga stimulacijska komponenta 1 uspostavlja gornju granicu struje prve komponente ne višu od struje na drugoj stimulacijskoj komponenti.
In a first embodiment, the invention provides a compound of Formula (A): or a pharmaceutically acceptable salt, or stereoisomer thereof; wherein 
Spoj, naznačen time, da ima formulu (A): ili njegova farmaceutski prihvatljiva sol, ili njegov stereoizomer; pri čemu
Parenteral dosage forms can be prepared by dissolving the compound of the invention in a suitable liquid vehicle and filter sterilizing the solution before filling and sealing an appropriate vial or ampoule. 
Parenteralni dozirni oblici se mogu dobiti otapanjem spoja prema izumu u prikladnom tekućem sredstvu i sterilizacijom filtriranjem otopine prije punjenja i zatvaranja odgovarajuće bočice ili ampule.
the three CDRs of the heavy chain variable region (VH): CDR4, CDR5 and CDR6 respectively set forth in SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6, wherein said ligand is selected from the group consisting of an antibody, a scFv fragment and a Fab fragment, wherein said ligand is for use in a method of treatment. A ligand comprising 
tri CDR-a varijabilne regije teškog lanca (VH): CDR4, CDR5 i CDR6 redom navedene u SEQ ID No. 4, SEQ ID No. 5 i SEQ ID No. 6, naznačen time da se navedeni ligand veže na anti-ligand koji se nalazi u sekvenci amino kiseline definiranoj sa SEQ ID No. 20 ili SEQ ID No. 32, te je navedeni ligand odabran iz skupine koja se sastoji od protutijela, scFv fragmenta i Fab fragmenta.
According to another embodiment of the present invention, the cPCC comprises aggregates having a weight median particle diameter d 50 value from 0.1 to 50.0 µm, preferably from 0.2 to 25.0 µm, more preferably from 0.3 to 10.0 µm and most preferably from 0.4 to 5.0 µm, measured according to the sedimentation method. 
Upotreba u skladu s patentnim zahtjevom 1 ili 2, naznačena time što cPCC sadrži agregate s vrijednošću težinski usrednjenog promjera čestica dsg od 0,2 do 25,0 um, poželjnije od 0,3 do 10,0 um, a najpoželjnije od 0,4 do 5,0 um, što je izmjereno postupkom taloženja.
The DNA-targeting RNA provides target specificity to the complex by comprising a nucleotide sequence that is complementary to a sequence of a target DNA. 
(i) segment koji cilja na DNK 1 koji obuhvaća nukleotidnu sekvencu koja je komplementarna sekvenci u ciljanoj DNK, i
US 4,389,421 teaches the addition of organic compounds containing 1,8-epoxy groups, such as 1,8-cineole, to prevent or significantly reduce light struck flavour in malt beverages. 
US 4.389.421 govori o dodavanju organskih spojeva koji sadržavaju 1,8-epoksi skupine, kao što je 1,8-cineol, radi sprečavanja ili značajnog smanjivanja svjetlosnog udara na aromu kod pića na bazi slada.
Table 9: Determination of the density 
Broj objave europskog patenta:
A pharmaceutical composition comprising a compound as defined in any one of claims 1-14, for use in a method of treating an animal having type 1 myotonic dystrophy. 
Farmaceutski sastav, koji obuhvaća spoj kako je definirano u bilo kojem od zahtjeva 1-13, za upotrebu u postupku liječenja životinje koja ima tip 1 miotoničnu distrofiju.
The use of any one of the preceding items, wherein expression of the therapeutic protein in the vector is controlled by an ubiquitous, regulated and/or tissue-specific promoter. 
AAV vektor iz bilo kojeg od prethodnih patentnih zahtjeva, pri čemu je ekspresija terapijskog proteina kontrolirana sveprisutnim, reguliranim i/ili tkivno-specifičnim promotorom.
the manufacture of a medicament for the prophylaxis or treatment of a disease state or condition arising from abnormal cell growth; 
(c) proizvodnju lijeka za prevenciju ili liječenje bolesti ili stanja koje proizlazi iz abnormalnog rasta stanica;
providing injection line pieces (21) having a length dimension which is equal to the thickness dimension of a core element (4), 
- < izvedbu dijelova (21) injekcijske linije čija je dužina jednaka deljini jezgrenog elementa (4),
propyl substituted with C(=O)OR4, wherein R4 is an alkyl of 1 to 18 carbon atoms, alkenyl of 2 to 18 carbon atoms, or alkynyl of 2 to 18 carbon atoms; or 
propil supstituiran sa C(=O)OR4, gdje je R4 alkil sa 1 do 18 atoma ugljika, alkenil sa 2 do 18 atoma ugljika, ili alkinil sa 2 do 18 atoma ugljika; ili
The compound of claim 5, wherein R23 is -CH3. 
Spoj sukladno patentnom zahtjevu 5, naznačeno time, da R23 je -CHa.
A method according to claim 1, wherein component A) is a compound of formula I, wherein R1 is difluoromethyl, Y is ―CHR2- and R2 is isopropyl. 
Postupak prema zahtjevu 1, naznačen time, da je komponenta A) spoj sa formulom I, pri čemu R, je difluorometil, Y je -CHR-, te R, je izopropil.
Although the inventors do not wish to be bound by theory, it is believed that N-heterocyclic substances are capable of absorbing ultraviolet light without being decomposed into undesirable off-flavour generating substances. 
Iako izumitelji ne žele biti ograničeni teorijom, vjeruje se da su N-heterocikličke tvari sposobne za apsorbiranje ultraljubičastog svjetla bez da se raspadnu u neželjene tvari koje razvijaju ustajali okus.
The transgenic mouse of claim 1 or 2, wherein the mouse further comprises in its genome an endogenous k light chain immunoglobulin locus comprising a replacement of endogenous Vk and Jk gene segments with unrearranged human Vλ and Jλ gene segments, and wherein the human Vλ and Jλ gene segments are operably linked to an endogenous mouse Ck gene such that the mouse expresses an immunoglobulin light chain that comprises a human λ variable region fused with a mouse k constant region. 
Genetski modificirani miš prema zahtjevu 1, naznačen time, što miš u svom genomu dodatno sadrži endogeni lokus imunoglobulina lakog lanca K koji se sastoji od zamjene endogenih VK 1 JK genskih segmenta neraspoređenim humanim VA i JA genskim segmentima, te naznačen time, što su humani VA 1 JA genski segmenti operativno povezani s endogenim mišjim CK genom tako da miš izražava imunoglobulinski laki lanac koji sadrži humanu varijabilnu regiju A spojenu s mišjom konstantnom regijom K.
The composition or vaccine of any one of claims 1-8 for use in a method for inducing an immunogenic or protective response in an animal against one or more avian pathogens, said method comprising at least one administration of the composition or vector. 
Vektor prema zahtjevu 10, naznačen time, da se upotrebljava u postupku induciranja imunosnog ili zaštitnog odgovora kod životinje protiv jednog ili više ptičjih patogena, pri čemu navedeni postupak obuhvaća najmanje jednu primjenu spomenutog sastava ili cjepiva.
A compound according to claim 6 wherein R1 represents 2,2-dimethylpropyl. 
Spoj u skladu s patentnim zahtjevom 6, naznačen time, da R; predstavlja 2,2-dimetilpropil.
In one option, the pivoting movement of the mobile mass is in the same plane defined by the barrel and is between about 10 to about 70 degrees of displacement from the upward position to the lower and most-downward position. 
Vatreno oružje iz patentnih zahtjeva 1-6, pri čemu rotacijsko gibanje pomične mase (34) u vertikalnoj ravnini sadržava osi spremnika (21) 1 kreće se otprilike između 10 i 70 stupnjeva pomaka od gornje pozicije do donje pozicije.
a coordinating ether solvent that has low miscibility with water; or an ether solvent that has low miscibility with water and a coordinating co-solvent, provided that the coordinating co-solvent constitutes no more than about 20% v/v of the reaction mixture; 
(1) koordinacijsko etersko otapalo koji ima nisku mješavost sa vodom; ili (ii) etersko otapalo koje ima nisku mješavost sa vodom i koordinacijsko ko-otapalo, uz uvjet da koordinacijsko 10
The compound of item 25, wherein A1 is selected from the group consisting of substituted phenyl having one or two substituents and substituted pyridyl having one substituent, wherein each substituent is independently selected from the group consisting of halo, cyano, hydroxy, amino, haloalkyl, alkoxy, haloalkoxy, and alkyl, or a pharmaceutically acceptable salt, solvate, or prodrug thereof. 
R!" je odabran iz grupe koja se sastoji od: a) = vodika; b) -hidroksi;i c) alkila ili njena farmaceutski prihvatljiva sol ili solvat; ili iv) R*je hidroksialkil ili hidroksi(cikloalkil)alkil, ili njena farmaceutski prihvatljiva sol ili solvat, i gdje je navedeni hidroksialkil ili hidroksi(cikloalkiljalkil poželjno odabran iz grupe koja se sastoji od:
In one embodiment, X is —CH(R15)—OR16, which can be depicted as formula e: 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je X je -CH(R'*)-OR'* i ima formulu e:
A compound of formula III Wherein 
1. Spoj formule III X
Vinification tank equipped with a device for the injection of air or inert gas into the vinification tank (1), wherein the device for the injection of air or inert gas comprises: 
Vinifikacijski spremnik opremljen uređajem za injektiranje zraka u vinifikacijski spremnik (1), gdje uređaj za injektiranje zraka sadrži:
Preferably, the bendamustine concentration is from about 20 mg/mL to about 50 mg/mL, more preferably from about 25 mg/mL to about 50 mg/mL. 
Stabilan pri dugotrajnom skladištenju, nevodeni tekući pripravak s bendamustinom prema zahtjevu 7, naznačen time, da je stabilizirajuća količina antioksidansa od 5 mg/mL do 20 mg/mL.
The cell of claim 7, wherein the domain capable of eliciting an immune response is selected from the Mycobacterium antigens Ag85B (M.tuberculosis), Ag85B (M.bovis), Ag85A (M.tuberculosis) and ESAT-6 (M.tuberculosis) or an immunogenic fragment thereof. 
Stanica prema zahtjevu 7, naznačena time što se domena sa sposobnošću izazivanja imunog odgovora bira između mikobakterijskih antigena Ag85B (M.tuberculosis), Ag85B (M.bovis), Ag85A (M.tuberculosis) i ESAT-6 (M.tuberculosis) ili njihovih imunogenih fragmenata.
Therapy with antibacterial agents administered in the oral preparations employed today has at least two limitations. 
Današnje liječenje antibakterijskim agensima koji se daju u pripravcima za oralno uzimanje ima barem dva ograničenja.
The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R1a, R2a, R3a, R1b, R2b, and R3b are each independently a hydrogen atom, a halogen atom, a C1-6 alkyl group, a halo-C1-6 alkyl group, a C1-6 alkoxy group, or a phenyl group; and R4a is a phenyl group substituted by a halogen atom, a cyano group, a C1-6 alkyl group, a halo-C1-6 alkyl group, a C1-6 alkoxy group, a halo-C1-6 alkoxy group, a methylenedioxy group, an ethyleneoxy group, or a mono- or di-C1-6 alkylamino group; or a heterocyclyl group substituted by a halogen atom, a cyano group, a C1-6 alkyl group, or a C1-6 alkoxy group. 
Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol, naznačen time što svaki od R1a, R2a, R3a, R1b, R2b i R3b je neovisno atom vodika, atom halogena, C1-6 alkilna skupina, halogen-C1-6 alkilna skupina, C1-6 alkoksi skupina ili fenilna skupina; i a je fenilna skupina, supstituirana s atomom halogena, cijano skupinom, C1-6 alkilnom skupinom, halogen-C1-6 alkilnom skupinom, C1-6 alkoksi skupinom, halogen-C1-6 alkoksi skupinom, metilendioksi skupinom, etilenoksi skupinom ili mono- ili di-C1-6 alkilamino skupinom; ili heterociklilna skupina, supstituirana s atomom halogena, cijano skupinom, C1-6 alkilnom skupinom ili C1-6 alkoksi skupinom.
After this time, the reaction mixture was concentrated under reduced pressure. 
Nakon ovog vremena reakcijska smjesa je koncentrirana pod smanjenim tlakom.
A composition according to claim 1, wherein component (A) is 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbomene-5-yl)amide and component (B) is selected from azoxystrobin and picoxystrobin. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-iljamid, te kao komponentu (B) fluopiram.
The device according to claim 2, characterized in that the second support comprises two parts joined by screws. 
Naprava prema zahtjevu 1, naznačena time što drugi nosač (103) sadrži dva dijela koja su spojena vijcima (105).
condensing the expanded DPFs into cell aggregates that exhibit the size and shape of the physiological DP, wherein said DPFs are differentiated in non-adhesive culture vessels in a cell concentration per vessel surface of 1,000 to 100,000 DPFs/cm2, and wherein the expanded DPFs are condensed for at least 48 h; 
(d) kondenziranja ekspandiranih DPF-ova u stanične agregate koji iskazuju veličinu 1 oblik fiziološke DP, pri čemu su navedeni DPF-ovi diferencirani u ne-adhezivnim posudama sa kulturom u staničnoj koncentraciji na površini posude od 1.000 do 100.000 DPF/cm', te
A passenger vehicle according to claim 6, characterised in that the body (2) comprises at least one guide element (13), along which a movable roof element is guided upon movement thereof. 
Autobus u skladu s patentnim zahtjevom 3, naznačen time što tijelo sadrži najmanje jedan vodeći element, duž kojeg se vodi pokretni krovni element prilikom svog gibanja.
the prevention of latent tuberculosis; 
(b) sprječavanje latentne tuberkuloze;
Pharmaceutical compositions having improved dissolution profiles for poorly soluble drugs 
FARMACEUTSKE SMJESE S POBOLJŠANIM PROFILOM OTAPANJA ZA SLABO TOPLJIVE LIJEKOVE
The process of any one of claims 1-7 containing a further step of mixing the conjugate with further antigens optionally wherein the further antigens comprises at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 S.pneumoniae saccharides selected from the group consisting of 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1-7, naznačen time što uključuje dodatni korak miješanja konjugata s dodatnim antigenima, gdje dodatni antigeni mogu sadržavati najmanje 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 ili 20 saharida iz bakterije S. pneumoniae, koje se bira iz skupine koju čine 1, 2, 3, 4, 5, GA, 6B, TF, 8, JN, JV, 10A, ITA, 12F, 14, 15B, 1I7F, 18C, 19A, 19F, 20, 22F, 23F 1 33F.
The aqueous slurry composition of claim 8, wherein the lithium-doped potassium silicate comprises potassium and lithium in the ratio of about 7:1 to 11:1 by weight as K2O:Li2O, and further wherein the ratio of silicate to potassium is of about 2.4:1 to 2.8:1 by weight as SiO2:K2O. 
Gusta smjesa 1z patentnog zahtjeva 2, pri čemu kalijev silikat obogaćen litijem sadrži kalij i litij u masenom omjeru 7:1 do 11:1 kao K20:L120, i nadalje gdje je maseni omjer silikata prema kaliju od 2.4:1 do 2.8:1 kao SiO»:K20.
Other Examples of Embodiments of the Invention Include 
Datum objave europske prijave patenta:
To the reaction mixture, 160 ml of toluene was further added and cooled. 
Nadalje je reakcijskoj smjesi dodano 160 ml toluena te je ohlađena.
A control system (1) comprising a pressure controller (2) to control the pressure of a conduit that transports explosive gas, said pressure controller comprising: 
Kontrolni sustav (1) obuhvaća: - regulator tlaka (2) za kontrolu tlaka tekućine u cijevi koja transportira eksplozivne plinove, spomenuti regulator tlaka sastoji od:
The corrugated side wall 2 has a plurality of annular ribs 3 which protrude radially outward alternating with a plurality of annular ribs 4 which protrude radially inward. 
Valovita bočna stijenka 2 sadrži mnoštvo prstenastih nabora 3 koji se radijalno pružaju ka vani i naizmjenično se smjenjuju sa mnoštvom prstenastih nabora koji se radijalno pružaju ka unutrašnjosti.
through a 0.22µm filter; pharmaceutical formulation (see below); lyophilisation; packaging; etc. 
kroz 0,22um filter; farmaceutskoj formulaciji (vidi dolje); liofilizaciji, pakiranju i t.d.
The method according to claim 1, wherein the sealing material is attached to the outer face of the capsule by gluing, welding, press-fitting, crimping or combinations thereof. The method according to claim 1, wherein the sealing material has a thickness of 0.3 mm to 2.5 mm. The method according to claim 1, wherein the engaging surface of the enclosing member presents corrugations which are at least substantially closed by the pressurized sealing material. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, u kojemu je materijal za brtvljenje (8) pričvršćen na vanjsku površinu čahure (1) pomoću lijepljenja, zavarivanja, pričvršćivanja utiskivanjem i/ili uvijanja. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, u kojemu materijal za brtvljenje (8) ima debljinu od 0.3 mm do 2.5 mm, poželjno 0.5 do 2 mm.
A sustained-release pharmaceutical composition comprising quetiapine or its salt and lambda-carrageenan, wherein the composition is present in the form of a tablet. 
Farmaceutski pripravak s produljenim otpuštanjem, koji sadrži kvetiapin, ili njegovu sol, i λ-karagenan, naznačen time što navedeni pripravak dolazi u obliku tablete.
A refractory foam filter producible by the method of any preceding claim comprising a three-dimensional network of strands of refractory material and having at least one side face and two opposed through-flow faces, the at least one side face having a unitary closed edge, and wherein the closed edge comprises cavities. 
Vatrostalni filtar od pjene koji se može proizvesti postupkom prema bilo kojem od prethodnih zahtjeva, a obuhvaća trodimenzionalnu mrežu niti vatrostalnog materijala i ima barem jednu bočnu stranu i dvije nasuprotne protočne strane, barem jedna bočna strana ima jedinstveni zatvoreni rub i gdje zatvoreni rub ima šupljine.
For the determination of θ1 for accepting the alternative hypothesis, the sample is assumed to be obtained from a pregnant woman carrying a trisomy 21 fetus. 
Postupak prema zahtjevu 1, naznačen time, da biološki uzorak je krv, plazma, serum, urin ili slina od trudnice.
The Wave-generating apparatus (1), according to claim 4, wherein the profile (5) comprises a rigid bar (16) in its interior in an adjustable position so that the shape of the profile (5) may be changed. 
Uređaj za generiranje valova (1), sukladno zahtjevu 4, pri čemu profil (5) obuhvaća čvrstu šipku (16) u unutrašnjosti u prilagodljivom položaju tako da oblik profila (5) može biti promijenjen.
Advantageous embodiments of the above aspects include: 
Datum podnošenja europske prijave patenta:
In another experiment the binding of the bacterial protein having an Ig-like domain, beta-galactosidase, to MEP HYPERCEL® column was examined. 
U drugom je eksperimentu istraženo vezanje beta-galaktozidaze, bakterijskog proteina koji ima domenu sličnu imunoglobulinskoj, na kolonu MEP HyperCel.
The polypeptide of claim 1, wherein the valine at position 5 of the DE loop (SEQ ID NO: 39) is substituted with an amino acid selected from the group consisting of A, C, D, E, F, I, K, L, M, N, Q, S, or T. 
Polipeptid u skladu s patentnim zahtjevom 1, naznačen time što je valin na položaju 5 u petlji DE (SEQ ID NO: 39) zamijenjen aminokiselinom koju se bira iz skupine kojučine A,C,D,E,F,1,K,L,M,N, Q, SiT.
A process according to claim 5 wherein the amine salt NHR3R4.HCl used in step (b) is recrystallised from methanolldiethyl ether prior to use. 
Postupak u skladu s patentnim zahtjevom 5, naznačen time što se aminsku sol NHR/R*HCI, upotrijebljenu u koraku (b), prije upotrebe prekristalizira iz smjese metanol/dietil-eter.
The energy savings system of claim 1, wherein the energy savings device is configured to drive a plurality of loads. 
Sustav za uštedu energije iz zahtjeva 1, gdje je uređaj za uštedu energije izveden tako da pokrene pluralizam opterećenja.
The assembly as recited in claim 5 wherein said temperature control assembly comprises a timer. 
Sklop na način opisan u Zahtjevu 1 pri čemu navedeni sklop za kontrolu temperature (934) sadrži mjerač vremena.
Method according to any of the previous claims, wherein in step c) the measurement of the time required for the at least one capacitor to reach a specified charge value is taken at least twice and the second charge time t2 is obtained as the mean of the measurements taken. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se u koraku c) mjerenje vremena potrebnog da najmanje jedan kondenzator dosegne specificiranu vrijednost nabijenosti provodi najmanje dvaput, a drugo vrijeme nabijanja t se dobije kao prosjek provedenih mjerenja.
A highly concentrated, stable pharmaceutical anti-HER2 antibody formulation according to claim 10, wherein the concentration of the polysorbate is 0.02 % (w/v), 0.04 % (w/v) or 0.06 % (w/v), respectively. 
Visoko koncentrirana, stabilna farmaceutska formulacija protutijela anti-HER2 prema zahtjevu 10, naznačena time, da je koncentracija polisorbata 0,02 % (masa/volumen) ili 0,04 % (masa/volumen) ili 0,06 % (masa/volumen).
or a N-oxide, a pharmaceutically acceptable addition salt or a solvate thereof. 
ili njegov N-oksid, farmaceutski prihvatljiva adicijska sol ili solvat.
Formulation 4: Concentration, % (w/v) 
Koncentracija, % Koncentracija, % (t/v)
The present composition is suitable for stabilising a wide variety of beverages and food products against light induced flavour changes. 
Sadašnji pripravak je prikladan za stabiliziranje raznih pića i prehrambenih proizvoda na promjene arome inducirane svjetlom.
The bispecific antibody according to claim 19, wherein the disease is selected from the group consisting of: a TH2-mediated disease, an IL-4 and/or IL-13 mediated disease, an allergic disease, asthma, cancer, an autoimmune disease, a disease associated with abnormal production of IL-4 and/or IL-13, scleroderma and idiopathic pulmonary fibrosis. 
Humanizirano bispecifično protutijelo za uporabu prema zahtjevu 10, naznačeno time da je bolest odabrana iz skupine koju čine alergijska bolest, astma, rak, autoimuna bolest, skleroderma i idiopatska plućna fibroza.
According to a further aspect, the present invention also relates to the use of an angiotensin II receptor 1 (AT-1) antagonist (sartan), preferably of telmisartan for the manufacture of a pharmaceutical composition comprising a therapeutically effective amount of said angiotensin II receptor 1 (AT-1) antagonist for the treatment of a systemic disease in cats. 
Sartan za uporabu prema bilo kojem od zahtjeva 1 do 6, naznačen time, da se farmaceutski sastav primjenjuje na mački u terapeutski djelotvornoj količini koja dovodi do kumulativne intravenozne doze sartana od najmanje oko 0,025 mg po kilogramu tjelesne mase.